Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Sunnybrook Research Institute | OTHER |
| Canadian Institutes of Health Research (CIHR) | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
The incidence of diabetes in pregnancy is rising, with rates of 1 in 7 pregnancies globally. Metformin is used for type 2 diabetes (T2DM) outside of pregnancy and is now increasingly prescribed during pregnancy. There are some concerns as metformin crosses the placenta and effects on offspring exposed during pregnancy are unknown. Animal and human evidence indicate that metformin may create an atypical in-utero environment similar to under-nutrition which has been associated with adult obesity. This is supported by studies in children of mothers treated with metformin in other populations where an increase in childhood obesity was found at 4-9 years of age. We now have evidence from the MiTy trial, that offspring of metformin-exposed women with T2DM have less large infants and are less adipose at birth, but are also more likely to be small for gestational age (SGA). These effects could lead to benefit or harm in the long-term. Offspring of MiTy mothers are currently being followed up to 2 years. Given that long-term effects may not be evident until 5 years of age, it is imperative to follow these children longer.
Goals/Research Aims:To determine whether in-utero exposure to metformin, in offspring of women with T2DM, is beneficial or harmful in the long-term.
Research Questions: 1. In offspring of women with T2DM, how does treatment with metformin during pregnancy affect a) adiposity b) growth over time c) metabolic syndrome d) cognitive and behavioral measures:2. What factors predict altered childhood adiposity and insulin resistance in these offspring?
Primary Outcome: Body mass index (BMI) z-score.
Secondary Outcomes: 1) other measures of adiposity (i.e. skinfolds, 2) growth over time 3) measures of insulin resistance 4) adipocytokines 5)neurodevelopment
Expected Outcomes Given these increasing concerns, this study will inform the best treatment for pregnant mothers with diabetes by studying the long-term outcomes of children exposed to metformin during pregnancy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Metformin exposed in utero | Offspring of mothers who were exposed to metformin during pregnancy in the MiTy trial. | ||
| Placebo exposed in utero | Offspring of mothers who were not exposed to metformin during pregnancy in the MiTy trial. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Body Mass Index (BMI) z-score | Using WHO or other appropriate growth charts | 5-11 years of age |
| Measure | Description | Time Frame |
|---|---|---|
| Skinfold measurements | triceps, subscapular and suprailiac skinfold thicknesses | 5-11 years of age |
| Sum of skinfold measurements: | sum of triceps, subscapular and suprailiac skinfold thicknesses |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Offspring of women with type 2 diabetes who participated in the MiTy trial will be recruited for participation.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Siobhan Tobin, HonBSc | Contact | 416-480-5631 | mitytykes@sunnybrook.ca | |
| Gail Klein, MSc | Contact | 416-480-5632 | gail.klein@sunnybrook.ca |
| Name | Affiliation | Role |
|---|---|---|
| Denice Feig, MD | Mount Sinai Hospital, Toronto, ON, Canada | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Campbelltown Hospital | Recruiting | Campbelltown | New South Wales | Australia |
Not provided
Not provided
Not provided
Not provided
A blood sample will be taken to be analyzed for markers of metabolic syndrome.
| 5-11 years of age |
| Triceps skinfolds z-scores | Using WHO or other appropriate growth charts | 5-11 years of age |
| Ratio of the central to peripheral skinfold ratio | ratio of the central (suprailiac) to peripheral (triceps) skinfold ratio; | 5-11 years of age |
| Overweight and obesity status | Defined using WHO or other appropriate growth charts | 5-11 years of age |
| Waist circumference | Waist circumference measurement | 5-11 years of age |
| Waist to height ratio | Waist and height measurements | 5-11 years of age |
| Growth trajectory | Longitudinal growth outcomes will be assessed using adiposity measurements from the MiTy trial (newborns) and at 3, 6, 12, 18 and 24 months from the MiTy Kids trial, to ages 5-11 years in the MiTy Tykes trial. | 5-11 years of age |
| Fat mass | Using the Tanita SC-240 bioimpedance analyzer (BIA) | 5-11 years of age |
| Percentage of body fat | Using the Tanita SC-240 bioimpedance analyzer (BIA) | 5-11 years of age |
| Measures of insulin resistance and metabolic syndrome | The following measurements combined will contribute to the assessment of insulin resistance and metabolic syndrome: fasting glucose, fasting insulin, fasting insulin-to-glucose ratio, and the HOMA-IR, serum levels of leptin, adiponectin and lipids | 5-11 years of age |
| Neurocognitive development | Attention Deficit Hyperactivity Disorder (ADHD)-5 Rating scale | 5-11 years of age |
| Neurocognitive development | Children's Communication Checklist (CCC-2) | 5-11 years of age |
| Neurocognitive development | Social Responsiveness Scale (SRS-2) | 5-11 years of age |
| Mater Misericordiae | Recruiting | Brisbane | Queensland | Australia |
|
| Alberta Children's Hospital | Recruiting | Calgary | Alberta | T3B 6A8 | Canada |
|
| Stollery Children's Hospital | Recruiting | Edmonton | Alberta | T6G 2B7 | Canada |
|
| British Columbia Children's Hospital | Completed | Vancouver | British Columbia | V6H 3N1 | Canada |
| Children's Health Research Institute of Manitoba (CHRIM) | Completed | Winnipeg | Manitoba | R3E 3P4 | Canada |
| IWK Health Centre | Completed | Halifax | Nova Scotia | B3K 6R8 | Canada |
| St Joseph's Health Care | Recruiting | London | Ontario | N6A 4V2 | Canada |
|
| The Scarborough Hospital | Recruiting | Scarborough Village | Ontario | M1P 2V5 | Canada |
|
| Mount Sinai Hospital | Recruiting | Toronto | Ontario | Canada |
|
| Hospital Maisonneuve-Rosemont | Recruiting | Montreal | Quebec | H1T 2M4 | Canada |
|
| Chuq-Chul | Completed | Québec | Quebec | G1V 4G2 | Canada |
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D011254 | Pregnancy in Diabetics |
| D063766 | Pediatric Obesity |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D009765 | Obesity |
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided